多发性骨髓瘤临床试验招募信息（全球在招）

这里汇总了全球正在招募患者的 多发性骨髓瘤（国际通用名 multiple myeloma）新药临床试验，包含试验分期、招募状态、开展国家和研究团队联系方式，全部以中文呈现。数据实时来自全球最大的临床试验注册库 ClinicalTrials.gov。本页同时覆盖骨髓瘤等说法。

正在招募的多发性骨髓瘤新药试验

• Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

  II 期招募中英国NCT06762769

• The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  III 期招募中英国NCT03562169

• Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

  II 期招募中美国NCT05847569

• IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

  II 期招募中中国NCT07509086

• AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

  I 期 / II 期招募中美国NCT05850234

• BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

  I 期 / II 期招募中中国NCT04271644

• A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  I 期 / II 期招募中美国法国西班牙NCT05828511

• A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

  III 期招募中美国NCT07582432

• A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  I 期招募中澳大利亚NCT07558915

• Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

  II 期招募中美国NCT05091372

• A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

  I 期招募中美国中国Israel日本NCT07409246

• Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma

  不适用招募中美国NCT06145581